Acorda Therapeutics Launches First-Ever Online Talk Show Focusing on Walking Problems in Multiple Sclerosis
MS patient advocate Kristie Salerno Kent to host debut on World MS Day
HAWTHORNE, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc. (ACOR), makers of Ampyra® (dalfampridine), today announced the launch of Ampyra Dialogues, the first-ever online talk show where patients and medical experts talk about how walking problems affect people living with MS. The first edition of Ampyra Dialogues debuts on World MS Day, Wednesday, May 30, 2012 on www.AmpyraJourneys.com.
Patient advocate Kristie Salerno Kent, an entertainer and educator who has worked to help people across the U.S. to understand the impact of MS, will host the series. In the debut of Ampyra Dialogues, Kristie interviews an MS patient and her family about their experience living with MS and how walking problems have affected each of them. In future editions Kristie will interview medical experts who specialize in treating people living with MS, including Ben Thrower, M.D., and Tracy Walker, NP, WOC, both from the MS Institute at the Shepherd Center in Atlanta, GA, one of the nations leading centers for the treatment of MS.
I have spoken with hundreds of people living with MS all around the world, and for so many of them, they simply do not know that a cane or walker is not necessarily their only option if they have a walking problem, said Kristie. Through Ampyra Dialogues, I want to use real life experiences from both patients and medical experts to show more people living with MS that you can do something about walking problems. I want this program to inspire people to talk to their doctor about walking.
Ampyra Dialogues is just one of many educational initiatives available on www.AmpyraJourneys.com, the website that features information and patient perspectives on walking problems associated with MS. The site also features a guide specifically for people living with MS on speaking to their doctor about walking problems. Ampyra is an oral medication developed by Acorda Therapeutics and approved by the FDA in 2010 as a treatment to improve walking in patients with multiple sclerosis. This was demonstrated by an increase in walking speed.
Walking impairment is one of the most common and debilitating effects of MS, and often is not addressed optimally. The Ampyra Dialogues program will help people living with MS obtain the information and encouragement they need to address their walking issues as effectively as possible, said Ron Cohen, MD, president and CEO of Acorda Therapeutics. We are launching this program on World MS Day to underscore the importance for people living with MS, their care partners and healthcare providers to engage in this important discussion.
Important Safety Information
Do not take AMPYRA if you have ever had a seizure or have certain types of kidney problems. The risk of having a seizure is higher in patients with certain types of kidney problems. AMPYRA should not be taken with other forms of 4-aminopyridine (4-AP, fampridine), since the active ingredient is the same. AMPYRA may cause serious side effects, including kidney or bladder infections. The most common side effects of AMPYRA include urinary tract infection, trouble sleeping, dizziness, headache, nausea, weakness, back pain, and problems with balance. The majority of side effects reported in the clinical trials were mild and transient. Take AMPYRA exactly as your doctor tells you to take it. Take AMPYRA tablets whole. Do not break, crush, chew or dissolve AMPYRA tablets before swallowing. Do not take 2 doses at the same time. Before taking Ampyra tell your doctor if you are pregnant or plan to become pregnant. It is not known if AMPYRA will harm your unborn baby. Tell your doctor if you are breast feeding or plan to breast feed. It is not known if AMPYRA passes into your breast milk. You and your doctor should decide if you will take AMPYRA or breast-feed. You should not do both.
About AMPYRA ® (dalfampridine)
AMPYRA is a potassium channel blocker approved as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. AMPYRA, which was previously referred to as Fampridine-SR, is an extended release tablet formulation of dalfampridine (4-aminopyridine, 4-AP), and is known as prolonged-, modified, or sustained-release fampridine (FAMPYRA®) in some countries outside the United States (U.S).
In laboratory studies, dalfampridine extended release tablets has been found to improve impulse conduction in nerve fibers in which the insulating layer, called myelin, has been damaged. AMPYRA is being developed and commercialized in the U.S. by Acorda Therapeutics; FAMPYRA is being developed and commercialized by Biogen Idec in markets outside the U.S. based on a licensing agreement with Acorda. AMPYRA and FAMPRYA are manufactured globally by Alkermes Pharma Ireland Limited, a subsidiary of Alkermes plc, based on a supply agreement with Acorda.
AMPYRA is available by prescription in the United States. For more information about AMPYRA, including patient assistance and co-pay programs, healthcare professionals and people with MS can contact AMPYRA Patient Support Services at 888-881-1918.
AMPYRA Patient Support Services is available Monday through Friday, from 8:00 a.m. to 8:00 p.m. Eastern Time at 888-881-1918. For full U.S. Prescribing Information and Medication Guide, please visit: www.AMPYRA.com.
About Acorda Therapeutics
Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with MS, spinal cord injury and other neurological conditions.
Acorda markets AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg, in the United States as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. AMPYRA is marketed outside the United States as FAMPYRA® (prolonged-release fampridine tablets) by Biogen Idec under a licensing agreement from Acorda. AMPYRA® and FAMPYRA® are manufactured under license from Alkermes Pharma Ireland Limited.
The Company also markets ZANAFLEX CAPSULES® (tizanidine hydrochloride) and Zanaflex® (tizanidine hydrochloride) tablets.
Acorda also receives sales royalties on tizanidine hydrochloride capsules, an authorized generic version of ZANAFLEX CAPSULES distributed by Watson Pharmaceutics, Inc. under its agreement with Acorda.
Acorda is developing an industry-leading pipeline of novel neurological therapies. Acorda is developing clinical stage compounds AC105 for acute treatment of spinal cord injury and GGF2 for treatment of heart failure. GGF2 is also being investigated in preclinical studies as a treatment for neurological conditions such as stroke and spinal cord injury. Additional preclinical programs include rHIgM22, a remyelinating monoclonal antibody for the treatment of MS, and chondroitinase, an enzyme that encourages nerve plasticity in spinal cord injury.
Erica Wishner, 914-347-4300 x4162
Source: Acorda Therapeutics, Inc.Copyright Business Wire 2012